San Diego, California–(Newsfile Corp. – April 5, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“ Tryp” or the “Company“) a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today it has initiated quoting activity on the OTCQB® Venture Market (the “OTCQB“) and is eligible for settlement and transfer of its common shares in…

Source

Previous articleEntheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test
Next articleMydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical